Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genelabs Withdraws Prasterone Application In Europe; U.S. Confirmatory Trial Stays On Schedule

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is seeking a partner for Europe to assist in future regulatory discussions after data were deemed insufficient. An additional U.S. trial confirming prasterone's effects on bone loss is expected to be complete by year-end.

You may also be interested in...

Genelabs' Prestara Phase III Does Not Confirm Bone Mineral Density Effect

The trial was designed to meet FDA's "approvable" letter request for confirmation of bone mineral density increases in women with lupus receiving glucocorticoids. Genelabs plans to meet with the agency when it completes data analysis.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts